Replies to post #423980 on NorthWest Biotherapeutics Inc (NWBO)

[sukus]

Now I realized it is so critical to have the definition changed by WHO. Without this GBM definition defined correctly, people would start asking question already like what we just witnessed today. And this is just in a message board. But I already feel the questions very intense.

[Nick119]

I should of clarified, what I meant was not the trial, but idh mutation status redefinition as non-GBM in terms of number of patients in the NWBO trial. But you answered my question in one of the previous posts of being roughly 12%.

thank you!

[exwannabe]

Probably not at all. It’s likely Dr. Weller had different demographics, but he is still holding them back from publication. Please see my last two posts.

I think the world started figuring out the idh mutation game, and that’s why it is no longer included in the definition of GBM.

We will see soon (no scare quotes needed).

As far as IDH, all you have read is the abstract. These are limited in size.

Your focus on IDH misses a point. If will make the trial comps more difficult as the data will not fully exit for the comps.

A few things we do know w/o seeing the full paper.

The no baseline corticosteroid group lived a couple months longer overall. The DCVax-L trial requires for patients to be steroid free for 10 days prior to leuko.

DCVax-L trial was age 18-70, 548 was 18+

DCVax-L required intent for near total resection, 548 only 20% actual resection.

Going be hard for the -L trial meth patient to have worse demographic.